1 trillion won technology export contract in January last year...Get 150 billion won in total. ablbio announced on the 2nd that it will receive $25 million (31.7 billion won) in short-term stages following the first administration of the dual antibody "ABL301" from Sanofi. The milestone is 594.2% of ablbio's sales of 5.3 billion won as of the end of last year. According to the contract, ablbio will receive the milestone within February 14. ABL301 is a candidate substance for the treatment of degenerative brain diseases such as Parkinson's disease, which ablbio exported technology to Sanofi in January last year. According to the contract, when ablbio completes the preclinical and phase 1 clinical trial, Sanofi proceeds